PA
JANX icon

Parallel Advisors’s Janux Therapeutics JANX Stock Holding History

Parallel Advisors’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.07K Hold
135
– – ﹤0.01% 3512
2026
Q1 		$1.88K Sell
135
-251
-65% -$3.44K ﹤0.01% 3395
2025
Q4 		$5.33K Hold
386
– – ﹤0.01% 2823
2025
Q3 		$9.43K Buy
+386
New +$9.4K ﹤0.01% 2550
2025
Q2 		– Sell
-7
Closed -$189 – 3634
2025
Q1 		$189 Buy
7
+5
+250% +$188 ﹤0.01% 3391
2024
Q4 		$107 Sell
2
-20
-91% -$1.06K ﹤0.01% 3428
2024
Q3 		$999 Buy
+22
New +$957 ﹤0.01% 3036

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Parallel Advisors's JANX Position: Q2 2026 in Review

Parallel Advisors held its Janux Therapeutics (JANX) position steady in Q2 2026 at 135 shares worth $2.07K. The position accounts for ﹤0.01% of the portfolio, ranked #3512.

Parallel Advisors first reported a position in JANX in Q3 2024 and has held it in 7 quarters since. The position peaked at $9.43K in Q3 2025. 197 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Parallel Advisors held 135 shares of Janux Therapeutics worth $2.07K as of Q2 2026.
  • Parallel Advisors left its Janux Therapeutics share count unchanged in Q2 2026.
  • Janux Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3512 holding.
  • Parallel Advisors first reported a position in Janux Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Parallel Advisors's Janux Therapeutics position peaked at $9.43K in Q3 2025.
  • 197 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.